WordNet

a chronic skin disease characterized by dry red patches covered with scales; occurs especially on the scalp and ears and genitalia and the skin over bony prominences

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 乾癬性関節炎の臨床症状および診断 clinical manifestations and diagnosis of psoriatic arthritis
2. 乾癬性関節炎の治療 treatment of psoriatic arthritis
3. 乾癬の治療 treatment of psoriasis
4. 滴状乾癬 guttate psoriasis
5. 乾癬における併存疾患 comorbid disease in psoriasis

Koryürek ÖM1, Kalkan G2.
Cutaneous and ocular toxicology.Cutan Ocul Toxicol.2016 Jun;35(2):145-52. doi: 10.3109/15569527.2015.1049356. Epub 2015 May 29.
Tocilizumab (TCZ) is a recombinant-humanized anti-human interleukin 6 receptor monoclonal antibody of the immunoglobulin (Ig) IgG1 subclass with a H2L2 polypeptide structure. Even if it was approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, systemic juvenile i
PMID 26023856

Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.

García-Doval I1,2, Pérez-Zafrilla B1,3, Ferrandiz C4, Carretero G5, Daudén E6, de la Cueva P7, Gómez-García FJ8, Herrera-Ceballos E9, Belinchón-Romero I10, Sánchez-Carazo JL11, López-Estebaranz JL12, Alsina M13, Ferrán M14, Torrado R5, Carrascosa JM4, Rivera R15, Vanaclocha F15; BIOBADADERM Study Group.
The Journal of dermatological treatment.J Dermatolog Treat.2016 Jun;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25.
BACKGROUND: Identifying patients likely to have very good or bad results from systemic psoriasis therapy could improve efficiency of therapy.OBJECTIVE: To develop prognostic models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis.METHODS: Multivariable logi
PMID 26367799

Haber SL1, Hamilton S2, Bank M2, Leong SY2, Pierce E2.
The Annals of pharmacotherapy.Ann Pharmacother.2016 Apr;50(4):282-90. doi: 10.1177/1060028015627467. Epub 2016 Jan 18.
OBJECTIVE: To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the treatment of psoriasis and psoriatic arthritis.DATA SOURCES: A PubMed search (1946 to December 2015) using the terms apremilast and CC-10004 was conducted to identify rele
PMID 26783350